06160.HK
BeOne Medicines Ltd.
HKSE · Healthcare · Biotechnology · CH
HKD 212.60
+0.76%Aug 31, 2026, 19:14 UTC
President Donald J. Trump announced agreements with nine additional pharmaceutical manufacturers to lower drug prices for Americans in line with most-favored-nation pricing.
Aug 31, 2026, 19:00 UTC
BeOne Medicines announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients and strengthen its U.S. manufacturing footprint.
Source:Aug 18, 2026, 10:00 UTC
BeOne Medicines, BeOne Care Foundation, and The Max Foundation renewed their partnership through 2028 to expand access to BRUKINSA for chronic lymphocytic leukemia treatment in low- and middle-income countries.
Source:Aug 10, 2026, 10:00 UTC
BeOne Medicines and Revolution Medicines announced a multi-part collaboration including clinical development and regional commercialization of drug combinations.
Aug 5, 2026, 12:07 UTC
BeiGene's new drug Baiyueda (sonrotoclax) received accelerated approval from the US FDA for treating adult patients with relapsed or refractory mantle cell lymphoma.
Source:Aug 5, 2026, 12:07 UTC
BeiGene reported H1 2026 results with net profit of 3.271 billion yuan, up 6.27 times year-on-year, and revenue of 22.22 billion yuan, up 26.8% year-on-year.
Aug 5, 2026, 00:00 UTC
BeOne Medicines Ltd. reported Q2 2026 financial results with total revenue of $1.705 billion, GAAP diluted EPS of $2.05, and non-GAAP diluted EPS of $3.84.
Jun 30, 2026, 10:00 UTC
BeOne Medicines announced positive Phase 3 results for BRUKINSA in frontline mantle cell lymphoma from the MANGROVE study.
Source: